Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Annals

Glutamate and Disorders of Cognition and Motivation

Edited by Edited by Bita Moghaddam (Yale University School of Medicine, New Haven, CT) and Marina E. Wolf (Chicago Medical School, North Chicago, IL)
Glutamate and Disorders of Cognition and Motivation

Published: November 2003

Volume 1003

Learn More

Although glutamate-mediated neurotransmission has long been implicated in neurodegenerative disorders, the major focus of research on cognitive, affective, and addictive disorders has been on monoamine (dopamine, serotonin, norephinephrine) systems in the brain. About 10–15 years ago, a few scientists began studying the possible role of glutamate in these disorders, led by awareness of glutamate's importance in cortical function and of the role of glutamatergic projections in governing the activity of monoaminergic neurons. Recent years have witnessed tremendous advances in our understanding of glutamatergic involvement in schizophrenia and drug abuse. This volume presents the latest research in both basic and clinical fields and will facilitate interactions among diverse disciplines and between basic and clinical scientists.